Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab with high- and low-dose radiotherapy for metastatic nasopharyngeal carcinoma
ChiCTR2300068022Phase 2Recruiting
- Sponsor
- The Second Affiliated Hospital of Nanchang University
- Start
- Feb 2023
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of toripalimab in nasopharyngeal carcinoma (NPC), sponsored by The Second Affiliated Hospital of Nanchang University. Primary endpoint: Objective remission rate. Started Feb 2023; status: recruiting.
02
Drugs
toripalimab
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on ChiCTR2300068022.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300068022.